TIGIT and neoplasm: TIGIT shows higher affinity to CD155, which is expressed on dendritic cells and tumor cells, than the immune-activating receptor CD226 (also known as DNAM1) on the cytotoxic T cells and NK cells, resulting in suppression of immune activation (63).